Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Pancreatic Neoplasms 6Uterine Cervical Neoplasms 4Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Liver Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Hodgkin Disease 2Glioma 2Esophageal Neoplasms 2Disease 2Colonic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Thoracic Neoplasms 1Thoracic Diseases 1Spinal Diseases 1

Interventions

Cyclophosphamide 53Vincristine 33blinatumomab 30Prednisone 28Methotrexate 28Cytarabine 26Dexamethasone 24Specimen Handling 21Rituximab 21Doxorubicin 20merphos 19Mercaptopurine 19Etoposide 18prednylidene 17fludarabine 17deltacortene 17Calcium Dobesilate 17Biopsy 17dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16azathiopurine 15Inotuzumab Ozogamicin 15pegaspargase 14venetoclax 13Leucovorin 13CT-P10 13Asparaginase 13Spinal Puncture 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Magnetic Resonance Imaging × 1 year × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡